Multiple Sclerosis Clinical Trials in Los Angeles

Showing 281-300 of 489 trials

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

NCT03359850

Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment, for the purpose of providing recommendations to guide the initial dose and dose titration in this patient population.

Ovarian NeoplasmsNeoplasmsSolid Tumor+1 more

Tesaro, Inc.17 participantsStarted Feb 2018

Los Angeles, California, United States • Newport Beach, California, United States • Aurora, Colorado, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

NCT00526045

This is a phase I/II, open-label, multicenter study of AUY922 administered intravenously in patients with advanced solid malignancies to determine the maximum tolerated dose. Phase II expansion arms will investigate efficacy in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer. Additional patients with advanced solid malignancies will also be investigated in a separate expansion arm. Safety, pharmacokinetics and pharmacodynamics will be assessed.

Breast CancerHematologic Neoplasms

Novartis Pharmaceuticals117 participantsStarted Jul 2007

Los Angeles, California, United States • Augusta, Georgia, United States • Boston, Massachusetts, United States +7 more locations

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Multiple Sclerosis Trials in Other Cities

Project Connect Online: An Internet-based Intervention for Women With Breast Cancer

Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

HPV IIS Reminder/Recall- New York State

Intrathecal Mafosfamide

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

National Marrow Donor Program Long-Term Donor Follow-Up

An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Other Conditions in Los Angeles